Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

NCT05286801 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05286801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05286801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 17, 2022
Completion date
March 31, 2030
Enrollment
86 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

atypical teratoid/rhabdoid tumor, epithelioid sarcoma, kidney medullary carcinoma, malignant solid neoplasm, poorly differentiated chordoma, recurrent atypical teratoid/rhabdoid tumor, recurrent chordoma, recurrent epithelioid sarcoma, recurrent kidney medullary carcinoma, recurrent malignant solid neoplasm, recurrent rhabdoid tumor, refractory atypical teratoid/rhabdoid tumor, refractory chordoma, refractory epithelioid sarcoma, refractory kidney medullary carcinoma, refractory malignant solid neoplasm, refractory rhabdoid tumor, rhabdoid tumor